PHC GROUPPHC Holdings Corporation

  • About Us
  • Group Companies
  • Products & Services
  • Sustainability
  • Investor Relations
  • Newsroom

About Us

About PHC GroupCEO MessageMission, Vision & ValuesValue Creation PlanHistory LeadershipPHC Group by the Numbers

Group Companies

Ascensia LSI Medience Wemex Mediford Epredia PHCbi PHC IVD

Products & Services

Cancer Pathology Biologic & Cell Preservation Diagnostic Testing Patient Record & Billing Software Diabetes Management Medical Device & Drug Delivery

Sustainability

Sustainability
  • CEO Message
  • Materiality
  • Sustainability Management
  • PHC GROUP Integrated Report
  • Stakeholder Engagement
  • Environment image
    Environment
  • Society image
    Social
  • Governance image
    Governance

Investor Relations

INVESTOR RELATIONS

MANAGEMENT

  • Corporate Governance
  • IR Basic Policy
  • Business Risks

IR LIBRARY

  • Financial Results
  • Presentation Materials
  • IR Materials
  • Historical Financial Data
  • PHC GROUP Integrated Report
  • Mid-term Plan
  • Our Group Introduction

STOCK INFORMATION

  • Stock Overview
  • General Meeting of Shareholders
  • Shareholder Newsletter
  • Stock Quotations
  • Analyst Coverage
IR News Financial Highlights IR Calendar Contact IR Disclaimer

Newsroom

NEWSROOM

NEWS

  • PHC Holdings Corporation
  • PHC Group Companies
CareersContact
JP

Other PHC Group Websites

  • Ascensia Diabetes Care Holdings AG
  • PHC Corporation
  • LSI Medience Corporation
  • Wemex Corporation
  • Mediford Corporation
  • Epredia Holdings Ltd.
  • PT PHC Indonesia
  • PHC Corporation of North America
  • PHC Europe B.V.
  • SciMed (ASIA) Pte Ltd
  • Amelieff Corporation

Other PHC Group Websites

  • Ascensia Diabetes Care Holdings AG
  • PHC Corporation
  • LSI Medience Corporation
  • Wemex Corporation
  • Mediford Corporation
  • Epredia Holdings Ltd.
  • PT PHC Indonesia
  • PHC Corporation of North America
  • PHC Europe B.V.
  • SciMed (ASIA) Pte Ltd
  • Amelieff Corporation
CareersContactJP
Newsroom > 2019 > PHC Holdings Signs Agreement to Acquire Anatomical Pathology Business from Thermo Fisher Scientific

News


2019

NewsJanuary 29

PHC Holdings Signs Agreement to Acquire Anatomical Pathology Business from Thermo Fisher Scientific

TOKYO, January 29, 2019 ―PHC Holdings Corporation (headquarters: Tokyo, Japan, hereafter PHCHD) today announced that it has signed a definitive agreement with Thermo Fisher Scientific Inc. (NYSE: TMO, hereafter Thermo Fisher), the world leader in serving science, to acquire Thermo Fisher’s Anatomical Pathology business for approximately US$1.14billion.

Thermo Fisher’s Anatomical Pathology business is one of the leading providers of microscope slides, instruments and consumables in the industry and is part of Thermo Fisher’s Specialty Diagnostics Segment, operating in the US, Europe and China with approximately 1,200 employees.

PHCHD is a global healthcare company that offers value-added products and services across diabetes care, diagnostics, life sciences and healthcare IT. Aiming to achieve further business growth, PHCHD will expand its business portfolio through the acquisition of the business from Thermo Fisher.

Hidehito Kotani, Ph.D. and CEO of PHCHD commented, “We are pleased to have signed the agreement with Thermo Fisher Scientific. Their anatomical pathology business has shown steady growth with their strong customer base in global hospital markets, especially in the United States. This is a solid business with good growth potential and we believe it will create value for our stakeholders as part of our growing diagnostics and healthcare portfolio.”

PHCHD currently expects to close the transaction in the second quarter of 2019, subject to customary closing conditions and the receipt of applicable regulatory approvals.

About PHC Holdings Corporation

Incorporated in 2014, PHC Holdings Corporation is a global healthcare company. Its subsidiaries include PHC Corporation and Ascensia Diabetes Care Holdings AG. Committed to its corporate mission, “We contribute to the wellbeing of society through our diligent efforts by creating new value propositions for all the people who wish for better health,” the company develops, manufactures, sells and services medical equipment and solutions across diabetes care, diagnosis, life sciences and healthcare IT. PHC Holdings Corporation group’s consolidated net sales in FY2017 was 192.6 billion yen with global distribution of products and services for more than 125 countries. PHC Holdings Corporation changed its name from Panasonic Healthcare Holdings Co., Ltd. in April, 2018.
For further information on PHC Holdings Corporation, please visit
www.phchd.com

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Its mission is to enable its customers to make the world healthier, cleaner and safer. Thermo Fisher Scientific helps its customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through its premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – the company offers an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit
www.thermofisher.com

Media contact

Corporate Communications Department
PHC Holdings Corporation
+81-3-6778-5311

  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
Terms of UsePrivacy PolicyFacebookLinkedIn © PHC Holdings Corporation All rights reserved.